Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status

Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status

Translational RelevanceEvaluation of targeted therapies is urgently needed for the majority of patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) who progress after immunochemotherapy. Erlotinib, a targeted inhibitor of epidermal growth factor receptor pathway, lacks FD...

Full description

Bibliographic Details
Main Authors: Mercedes Porosnicu, Anderson O’Brien Cox, Joshua D. Waltonen, Paul M. Bunch, Ralph D’Agostino, Thomas W. Lycan, Richard Taylor, Dan W. Williams, Xiaofei Chen, Kirtikar Shukla, Brian E. Kouri, Tiffany Walker, Gregory Kucera, Hafiz S. Patwa, Christopher A. Sullivan, J. Dale Browne, Cristina M. Furdui
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
head and neck cancer
erlotinib
[18FDG] PET/CT
smokers
women in science
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.939118/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.939118/full

Similar Items